Sorrento Therapeutics Invests In New Company, Celularity

San Diego-based biopharmaceuticals developer Sorrento Therapeutics announced on Monday that it has invested in a newly former company, Celularity, focused on treatment of cancer, inflammatory and degenerative diseases, and functional regeneration using placental technology. Sorrento said it will make a capital investment, and also provide certain immuno-oncology and cellular therapy intellectual property and assets to Celularity. Celularity will be headquartered in Warren, New Jersey. Size of the investment by Sorrento was not announced. Sorrento said it made its investment in creating Celularity along with Celgene Corporation, United Therapeutics, and Human Longevity Inc. More information »